GLP-1/Peptides

Dual GIP/GLP-1 agonist for weight loss and blood sugar control. Clinically proven efficacy up to −22% of initial body weight.

GLP-1 agonist for weight loss and type 2 diabetes treatment. The active ingredient in Ozempic and Wegovy with proven clinical efficacy.

A synthetic pentadecapeptide derived from a gastric protein. Studied in animals for tissue repair; no completed human trial exists.

A melanocortin analogue that darkens skin without ultraviolet light. Australia's TGA warns consumers against it.

Sold as thymosin beta-4, usually the seven-residue LKKTETQ fragment. The research is preclinical, and the compound is on the WADA prohibited list.

The most selective growth hormone secretagogue of its class: at standard doses it is described as leaving cortisol and prolactin unchanged.

A triple GLP-1/GIP/glucagon agonist in clinical trials. Phase 2 reported up to -24.2% body weight at 48 weeks.

Modified GRF (1-29). Produces pulsed growth hormone release, with a half-life of about 30 minutes.

A fragment of human growth hormone (amino acids 177-191), built for fat release without the blood-sugar effects. It failed its obesity trial and development stopped.

A synthetic four-amino-acid pineal peptide. Telomerase activation is reported largely by a single research group.

A copper tripeptide, permitted in cosmetics as a topical ingredient. The injected form is approved by no regulator.

Bremelanotide, FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Use by men is off-label.